News Author: Erilyn Riley Publish date: September 23, 2015
Photo courtesy of the
University of Pennsylvania
NEW YORK—The 5-year follow-up of the phase 1 trial of CTL019 in relapsed or refractory chronic ly...
News Author: Erilyn Riley Publish date: September 18, 2015
NEW YORK—For the first time, according to researchers, chimeric antigen receptor (CAR) T-cell therapy has been tested in a clinical trial in Sweden...
News Author: Erilyn Riley Publish date: July 8, 2015
Photo by Linda Bartlett LUGANO—The defucosylated monoclonal antibody (mAb) ARGX-110, which is active against CD70-bearing tumor cells and CD70-depe...
News Author: Erilyn Riley Publish date: July 5, 2015
LUGANO—The phase 1, first-in-human study of the novel SYK inhibitor TAK-659 is showing “good early evidence” of antitumor activity in patients with...
News Author: Erilyn Riley Publish date: July 2, 2015
Photo by Chad McNeeley
VIENNA—Outcomes of hematopoietic stem cell transplant (HSCT) are encouraging in myelofibrosis (MF) patients who respond well...
News Author: Erilyn Riley Publish date: July 2, 2015
VIENNA—New research indicates that duvelisib, a dual inhibitor of PI3Kδ and PI3Kγ, can generate rapid partial responses in treatment-naïve patients wi...
News Author: Erilyn Riley Publish date: June 30, 2015
Photo by Rhoda Baer
LUGANO—Long-awaited results of the Intergroup H10 trial in PET-positive Hodgkin lymphoma (HL) patients have shown that intensif...
News Author: Erilyn Riley Publish date: June 30, 2015
Photo by Larry Young LUGANO—Updated phase 1 results with TGR-1202 suggest this next-generation PI3kδ inhibitor lacks the hepatotoxicity associated ...
News Author: Erilyn Riley Publish date: June 25, 2015
Photo courtesy of UCLA
LUGANO—The PD-1 checkpoint inhibitor nivolumab produces rapid, durable, and, in some cases, “dramatic” responses in Hodgkin ...
News Author: Erilyn Riley Publish date: June 24, 2015
site of 13-ICML
LUGANO—Adding thiotepa and rituximab to the treatment of primary central nervous system (CNS) lymphoma is feasible from a safety pe...
News Author: Erilyn Riley Publish date: June 23, 2015
Photo by Jens Maus
LUGANO—Results of the RATHL trial indicate that bleomycin can be omitted from ABVD therapy following a negative interim FDG-PET ...
News Author: Erilyn Riley Publish date: June 22, 2015
Congress of the European
Hematology Association
VIENNA—Two very similar activin receptors, luspatercept and sotatercept, continue to show efficacy...
News Author: Erilyn Riley Publish date: June 22, 2015
thalassemia
VIENNA—Data from a phase 2a trial suggest the activin receptor sotatercept can effectively treat patients with ß-thalassemia.
Howeve...
News Author: Erilyn Riley Publish date: June 19, 2015
VIENNA—Researchers say they have found a way to unsickle red blood cells (RBCs), at least in vitro.
Using pegylated carboxyhemoglobin bovine gas tr...
News Author: Erilyn Riley Publish date: January 6, 2015
Credit: NIH
SAN FRANCISCO—Younger patients with Hodgkin lymphoma fare well on brentuximab vedotin, experiencing an overall objective response rate ...
